Junliang Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Junliang Fu has a total of 322 co-authors. Here are the top co-authors by number of shared publications:
- Fu-Sheng Wang
Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China
21 shared publications Xin Zhang
Senior Department of Infectious Diseases, Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases
8 shared publicationsRui Jia
Department of Gastroenterology, The 985th Hospital of Joint Logistic Support Force of Chinese PLA, Taiyuan 030001, China
6 shared publicationsXiaoning Zhang
Senior Department of Infectious Diseases, Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases
6 shared publicationsXiaoyan Li
Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
5 shared publications- Zheng Zhang
Shandong Key Laboratory of Healthy Food Resources Exploration and Creation, School of Food Sciences and Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250353, China
5 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1996565
Distinct plasma proteomic trajectories during PD-1 blockade and PEG-IFNα therapy are associated with HBsAg response in chronic hepatitis B
Background: PD-1 blockade and pegylated interferon-α (PEG-IFNα) are promising immunomodulatory strategies for chronic hepatitis B (CHB), but their systemic immune effects and response-associated proteomic patterns remain poorly defined. Methods: We performed longitudinal plasma proteomic profiling using the Olink Target 96 Inflammation panel in 25 nucleos(t)ide analogue-suppressed patients with CHB receiving PD-1 blockade (n=10) or PEG-IFNα (n=15). Plasma samples were collected at baseline, week 12, and week 24. Longitudinal protein changes were analyzed using linear mixed-effects models, and associations with week-24 HBsAg decline were evaluated using responder–non-responder comparisons and Spearman’s rank correlation. Responders were defined by an HBsAg decline of ≥1 log 10 IU/mL at week 24. Results: Seventy-seven proteins passed quality-control criteria. PEG-IFNα induced substantially broader longitudinal proteomic remodeling than PD-1 blockade, with most changes occurring within the first 12 weeks. Treatment-by-time analyses identified distinct trajectories between therapies, including differential changes in IL-18R1, TNF, CX3CL1, CXCL9, and CXCL10. Response-associated analyses suggested treatment-specific patterns: IL-10 was the leading exploratory signal in the PD-1 cohort, whereas IL-12B, CDCP1, and FGF-21 were more prominent in the PEG-IFNα cohort. These response-related associations did not remain significant after false discovery rate correction and were therefore considered exploratory. Conclusions: PD-1 blockade and PEG-IFNα induce distinct longitudinal circulating inflammatory proteomic programs in CHB. Favorable HBsAg decline was accompanied by treatment-specific rather than universal proteomic signatures, supporting the potential value of longitudinal proteomics for mechanistic and biomarker studies of HBV functional-cure strategies.
- 10 November 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1996565
Open AccessDistinct plasma proteomic trajectories during PD-1 blockade and PEG-IFNα therapy are associated with HBsAg response in chronic hepatitis B
Background: PD-1 blockade and pegylated interferon-α (PEG-IFNα) are promising immunomodulatory strategies for chronic hepatitis B (CHB), but their systemic immune effects and response-associated proteomic patterns remain poorly defined. Methods: We performed longitudinal plasma proteomic profiling using the Olink Target 96 Inflammation panel in 25 nucleos(t)ide analogue-suppressed patients with CHB receiving PD-1 blockade (n=10) or PEG-IFNα (n=15). Plasma samples were collected at baseline, week 12, and week 24. Longitudinal protein changes were analyzed using linear mixed-effects models, and associations with week-24 HBsAg decline were evaluated using responder–non-responder comparisons and Spearman’s rank correlation. Responders were defined by an HBsAg decline of ≥1 log 10 IU/mL at week 24. Results: Seventy-seven proteins passed quality-control criteria. PEG-IFNα induced substantially broader longitudinal proteomic remodeling than PD-1 blockade, with most changes occurring within the first 12 weeks. Treatment-by-time analyses identified distinct trajectories between therapies, including differential changes in IL-18R1, TNF, CX3CL1, CXCL9, and CXCL10. Response-associated analyses suggested treatment-specific patterns: IL-10 was the leading exploratory signal in the PD-1 cohort, whereas IL-12B, CDCP1, and FGF-21 were more prominent in the PEG-IFNα cohort. These response-related associations did not remain significant after false discovery rate correction and were therefore considered exploratory. Conclusions: PD-1 blockade and PEG-IFNα induce distinct longitudinal circulating inflammatory proteomic programs in CHB. Favorable HBsAg decline was accompanied by treatment-specific rather than universal proteomic signatures, supporting the potential value of longitudinal proteomics for mechanistic and biomarker studies of HBV functional-cure strategies.
- Open Access
- 12 October 2026
- Published by Wiley in Liver International
- Vol. 46 (11) , e70918
Safety, Tolerability and Antiviral Activity of GST ‐ HG131 in Chronic Hepatitis B: A Randomized, Double‐Blind Phase IIa Study
Background and Aims: Chronic hepatitis B (CHB) remains a major global health burden. Current therapies rarely achieve a functional cure due to low rates of HBsAg clearance, the persistence of the viral replication template—covalently closed circular DNA (cccDNA)—and the need for lifelong treatment. GST‐HG131 is a first‐in‐class, orally bioavailable small‐molecule inhibitor of PAPD5/7, key host factors involved in HBV mRNA stabilization and HBsAg production. We evaluated the safety, tolerability and antiviral activity of GST‐HG131 in patients with CHB receiving nucleos(t)ide analogue (NUC) therapy in a randomized, double‐blind, placebo‐controlled Phase IIa study. Methods: This double‐blind, randomized, placebo‐controlled Phase IIa study evaluated the efficacy and safety of GST‐HG131 in 45 CHB patients. Cohorts 1 and 2 ( n = 10 each; 8 active, 2 placebo) received 30 mg or 60 mg BID for 28 days, respectively. Cohort 3 ( n = 25; 20 active, five placebo) received 30 mg BID for 12 weeks. All participants were on nucleos(t)ide analog monotherapy for more than 6 months, with HBsAg between 100 and 1500 IU/mL, and serum ALT below 1× ULN. Results: At Day 28, HBsAg reductions were −0.65 log 10 IU/mL in the 30 mg BID 28‐day group and −0.53 log 10 IU/mL in the 60 mg BID 28‐day group. The 30 mg BID 12‐week group showed a greater reduction of −0.89 log 10 IU/mL at the end of treatment versus placebo ( p < 0.001). Two‐thirds of treated patients achieved a > 50% reduction in HBsAg with a maximum decrease of 1.64 log 10 IU/mL. Notably, 76.5% of patients in the 12‐week group achieved HBsAg below 100 IU/mL. Rebounds in HBsAg were observed following treatment discontinuation. GST‐HG131 was well tolerated, with no dose‐related toxicity or emerging safety concerns across all cohorts. Conclusion: GST‐HG131, a first‐in‐class oral PAPD5/7 inhibitor, demonstrated favourable safety and significant HBsAg reduction in patients with CHB. The greatest antiviral activity was observed after 12 weeks of treatment, supporting further clinical development of GST‐HG131 as a component of functional cure strategies for CHB. Trial Registration: ClinicalTrials.gov identifier: NCT06263959
- 12 October 2026
- Published by Wiley in Liver International
- Vol. 46 (11) , e70918
Open AccessSafety, Tolerability and Antiviral Activity of GST ‐ HG131 in Chronic Hepatitis B: A Randomized, Double‐Blind Phase IIa Study
Background and Aims: Chronic hepatitis B (CHB) remains a major global health burden. Current therapies rarely achieve a functional cure due to low rates of HBsAg clearance, the persistence of the viral replication template—covalently closed circular DNA (cccDNA)—and the need for lifelong treatment. GST‐HG131 is a first‐in‐class, orally bioavailable small‐molecule inhibitor of PAPD5/7, key host factors involved in HBV mRNA stabilization and HBsAg production. We evaluated the safety, tolerability and antiviral activity of GST‐HG131 in patients with CHB receiving nucleos(t)ide analogue (NUC) therapy in a randomized, double‐blind, placebo‐controlled Phase IIa study. Methods: This double‐blind, randomized, placebo‐controlled Phase IIa study evaluated the efficacy and safety of GST‐HG131 in 45 CHB patients. Cohorts 1 and 2 ( n = 10 each; 8 active, 2 placebo) received 30 mg or 60 mg BID for 28 days, respectively. Cohort 3 ( n = 25; 20 active, five placebo) received 30 mg BID for 12 weeks. All participants were on nucleos(t)ide analog monotherapy for more than 6 months, with HBsAg between 100 and 1500 IU/mL, and serum ALT below 1× ULN. Results: At Day 28, HBsAg reductions were −0.65 log 10 IU/mL in the 30 mg BID 28‐day group and −0.53 log 10 IU/mL in the 60 mg BID 28‐day group. The 30 mg BID 12‐week group showed a greater reduction of −0.89 log 10 IU/mL at the end of treatment versus placebo ( p < 0.001). Two‐thirds of treated patients achieved a > 50% reduction in HBsAg with a maximum decrease of 1.64 log 10 IU/mL. Notably, 76.5% of patients in the 12‐week group achieved HBsAg below 100 IU/mL. Rebounds in HBsAg were observed following treatment discontinuation. GST‐HG131 was well tolerated, with no dose‐related toxicity or emerging safety concerns across all cohorts. Conclusion: GST‐HG131, a first‐in‐class oral PAPD5/7 inhibitor, demonstrated favourable safety and significant HBsAg reduction in patients with CHB. The greatest antiviral activity was observed after 12 weeks of treatment, supporting further clinical development of GST‐HG131 as a component of functional cure strategies for CHB. Trial Registration: ClinicalTrials.gov identifier: NCT06263959
- Open Access
- 25 September 2026
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 15 (1) , 2735154
Sequential combination of anti-PD-1 antibody and PEG-IFNα in chronic hepatitis B patients: correlates of HBsAg loss with enhanced T-cell responses
Chronic hepatitis B virus (HBV) infection remains a major global health burden [1–3]. Achieving a functional cure – defined as sustained hepatitis B surface antigen (HBsAg) loss with or without ser...
- 25 September 2026
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 15 (1) , 2735154
Open AccessSequential combination of anti-PD-1 antibody and PEG-IFNα in chronic hepatitis B patients: correlates of HBsAg loss with enhanced T-cell responses
Chronic hepatitis B virus (HBV) infection remains a major global health burden [1–3]. Achieving a functional cure – defined as sustained hepatitis B surface antigen (HBsAg) loss with or without ser...
- Open Access
- 7 August 2026
- Published by Wolters Kluwer Health in Infectious Diseases & Immunity
- Vol. 6 (4) , 245-247
Bepirovirsen improves the functional cure of chronic hepatitis B through novel mechanisms
Was not provided for this article.
- 7 August 2026
- Published by Wolters Kluwer Health in Infectious Diseases & Immunity
- Vol. 6 (4) , 245-247
Open AccessBepirovirsen improves the functional cure of chronic hepatitis B through novel mechanisms
Was not provided for this article.
- Open Access
- 29 December 2025
- Published by Walter de Gruyter GmbH in Journal of Translational Internal Medicine
- Vol. 14 (1) , 123-133
Add-on PD-1 inhibitor with Peg-IFNα therapy favors functional cure of chronic hepatitis B patients
Background and Objectives: The treatment options for hepatitis B surface antigen (HBsAg) clearance are limited for patients who have failed pegylated interferon-α (Peg-IFNα) therapy. Given preclinical evidence that PD-1 blockade boosts antiviral immunity, this study aims to evaluate the efficacy and safety of PD-1 inhibitors in chronic hepatitis B (CHB) patients who have failed interferon therapy. Methods: This non-randomized controlled trial was conducted in CHB patients who failed to achieve HBsAg clearance after 48 weeks of Peg-IFNα therapy. Including two groups: (i) a PD-1 inhibitor plus Peg-IFNα group receiving sintilimab 1 mg/kg/12 weeks plus Peg-IFNα 180 μg/week ( n = 33) or (ii) a Peg-IFNα group continuing Peg-IFNα therapy ( n = 31). The primary endpoint was HBsAg clearance at week 24. Results: The PD-1 inhibitor plus Peg-IFNα group included 33 patients and the Peg-IFNα group included 31 patients. At week 24, HBsAg clearance occurred in 30.3% of PD-1 inhibitor plus Peg-IFNα group versus 9.7% of Peg-IFNα group ( P = 0.047). Median HBsAg declined by –0.916 log 10 IU/mL in the PD-1 inhibitor plus Peg-IFNα group compared with –0.067 log 10 IU/mL in Peg-IFNα group ( P = 0.013). In the PD-1 inhibitor plus Peg-IFNα group, alanine transaminase (ALT) rose transiently at week 12 only among patients who ultimately cleared HBsAg. Sintilimab increased stomatitis (12.1%) and recurrent fever (36.4%), but the frequency of grade ≥ 3 adverse events did not differ from Peg-IFNα group. Enzyme-linked immunosorbent assay (ELISA) profiling showed progressive induction of ISG15 after sintilimab, and patients achieving HBsAg clearance displayed higher baseline and week-12 OAS1 concentrations than non-clearers (both P < 0.05). Conclusions: Quarterly sintilimab add-on therapy triples the short-term HBsAg clearance rate in interferon-refractory CHB without major additional toxicity. A week-12 ALT surge and elevated OAS1 may serve as early biomarkers of response, but confirmation in larger randomized trials is needed.
- 29 December 2025
- Published by Walter de Gruyter GmbH in Journal of Translational Internal Medicine
- Vol. 14 (1) , 123-133
Open AccessAdd-on PD-1 inhibitor with Peg-IFNα therapy favors functional cure of chronic hepatitis B patients
Background and Objectives: The treatment options for hepatitis B surface antigen (HBsAg) clearance are limited for patients who have failed pegylated interferon-α (Peg-IFNα) therapy. Given preclinical evidence that PD-1 blockade boosts antiviral immunity, this study aims to evaluate the efficacy and safety of PD-1 inhibitors in chronic hepatitis B (CHB) patients who have failed interferon therapy. Methods: This non-randomized controlled trial was conducted in CHB patients who failed to achieve HBsAg clearance after 48 weeks of Peg-IFNα therapy. Including two groups: (i) a PD-1 inhibitor plus Peg-IFNα group receiving sintilimab 1 mg/kg/12 weeks plus Peg-IFNα 180 μg/week ( n = 33) or (ii) a Peg-IFNα group continuing Peg-IFNα therapy ( n = 31). The primary endpoint was HBsAg clearance at week 24. Results: The PD-1 inhibitor plus Peg-IFNα group included 33 patients and the Peg-IFNα group included 31 patients. At week 24, HBsAg clearance occurred in 30.3% of PD-1 inhibitor plus Peg-IFNα group versus 9.7% of Peg-IFNα group ( P = 0.047). Median HBsAg declined by –0.916 log 10 IU/mL in the PD-1 inhibitor plus Peg-IFNα group compared with –0.067 log 10 IU/mL in Peg-IFNα group ( P = 0.013). In the PD-1 inhibitor plus Peg-IFNα group, alanine transaminase (ALT) rose transiently at week 12 only among patients who ultimately cleared HBsAg. Sintilimab increased stomatitis (12.1%) and recurrent fever (36.4%), but the frequency of grade ≥ 3 adverse events did not differ from Peg-IFNα group. Enzyme-linked immunosorbent assay (ELISA) profiling showed progressive induction of ISG15 after sintilimab, and patients achieving HBsAg clearance displayed higher baseline and week-12 OAS1 concentrations than non-clearers (both P < 0.05). Conclusions: Quarterly sintilimab add-on therapy triples the short-term HBsAg clearance rate in interferon-refractory CHB without major additional toxicity. A week-12 ALT surge and elevated OAS1 may serve as early biomarkers of response, but confirmation in larger randomized trials is needed.
- Open Access
- 25 December 2025
- Published by Elsevier in Infectious Medicine
- Vol. 5 (1) , 100231
A brief review of chikungunya fever: From molecular virology to countermeasures
- 25 December 2025
- Published by Elsevier in Infectious Medicine
- Vol. 5 (1) , 100231
Open AccessA brief review of chikungunya fever: From molecular virology to countermeasures
- Open Access
- 6 November 2025
- Published by Springer Nature in Research Square
IL-4R+SELL+ Naïve B Cell Expansion correlates with functional cure in PEG-IFNα Treated Chronic Hepatitis B Patients
During chronic hepatitis B (CHB) infection, B cell dysfunction is a key contributor to viral persistence. Pegylated interferon alpha (PEG-IFNα) acts as an effective therapeutic agent for CHB by restoring immune responses directed against HBV, however, a comprehensive landscape of the B-cell responses associated with functional cure has not been fully elucidated. In this study, we employed single-cell RNA sequencing (scRNA-seq) and flow cytometry to quantitatively assess the B-cell subsets in nucleos(t)ide analog (NAs)-treated CHB patients receiving sequential PEG-IFNα add-on therapy. We identified two functionally distinct naïve B cell subsets (IL-4R + SELL + and IL-4R-SELL-) and three memory B cell populations in peripheral blood. Patients who achieved a functional cure displayed significantly elevated frequencies of total B cells and the IL-4R + SELL + naïve B cell subset, whereas memory B cell frequencies remained comparable between groups. In contrast to cured patients, uncured individuals exhibited sustained activation of type I interferon response pathways in both naive and memory B cells, which may be a key mechanism of B cell dysfunction. Notably, the frequency of IL-4R + SELL + naïve B cells during the treatment was inversely correlated with baseline HBsAg levels at the initiation of PEG-IFNα therapy, and has high predictive value for HBsAg loss following PEG-IFNα therapy. Our results indicate that CHB patients attaining functional cure after PEG-IFNα add-on therapy undergo a distinct B cell reconstitution, characterized by a pronounced expansion of peripheral IL-4R + SELL + naïve B cells. This finding highlights its dual significance as both a novel immunological biomarker and a potential therapeutic target for CHB functional cure.
- 6 November 2025
- Published by Springer Nature in Research Square
Open AccessIL-4R+SELL+ Naïve B Cell Expansion correlates with functional cure in PEG-IFNα Treated Chronic Hepatitis B Patients
During chronic hepatitis B (CHB) infection, B cell dysfunction is a key contributor to viral persistence. Pegylated interferon alpha (PEG-IFNα) acts as an effective therapeutic agent for CHB by restoring immune responses directed against HBV, however, a comprehensive landscape of the B-cell responses associated with functional cure has not been fully elucidated. In this study, we employed single-cell RNA sequencing (scRNA-seq) and flow cytometry to quantitatively assess the B-cell subsets in nucleos(t)ide analog (NAs)-treated CHB patients receiving sequential PEG-IFNα add-on therapy. We identified two functionally distinct naïve B cell subsets (IL-4R + SELL + and IL-4R-SELL-) and three memory B cell populations in peripheral blood. Patients who achieved a functional cure displayed significantly elevated frequencies of total B cells and the IL-4R + SELL + naïve B cell subset, whereas memory B cell frequencies remained comparable between groups. In contrast to cured patients, uncured individuals exhibited sustained activation of type I interferon response pathways in both naive and memory B cells, which may be a key mechanism of B cell dysfunction. Notably, the frequency of IL-4R + SELL + naïve B cells during the treatment was inversely correlated with baseline HBsAg levels at the initiation of PEG-IFNα therapy, and has high predictive value for HBsAg loss following PEG-IFNα therapy. Our results indicate that CHB patients attaining functional cure after PEG-IFNα add-on therapy undergo a distinct B cell reconstitution, characterized by a pronounced expansion of peripheral IL-4R + SELL + naïve B cells. This finding highlights its dual significance as both a novel immunological biomarker and a potential therapeutic target for CHB functional cure.
- Open Access
Safety and efficacy of PD-1 antibody combined with pegylated interferon α for functional cure in nucleos(t)ide analogues-suppressed chronic hepatitis B patients: protocol for a multicentre randomised controlled trial
Introduction The functional cure of chronic hepatitis B (CHB) is an ideal goal of therapy, as it is associated with improved long-term outcomes. Patients with low levels of HBsAg have higher rates of functional cure by pegylated interferon α (PEG-IFNα) therapy, and similar results have been observed in patients treated with PD-1 antibody. However, the combination therapy of PD-1 antibody and PEG-IFNα for promoting functional cure has not been studied. This study protocol aims to evaluate the efficacy and safety of a novel combined strategy, PD-1 antibody combined with PEG-IFNα therapy, in nucleos(t)ide analogues (NAs)-treated CHB patients. Methods and analysis This is a prospective, multicentre, open-label, randomised controlled study. Virologically suppressed CHB patients by NAs therapy will be recruited and randomised into PEG-IFNα group, PD-1 antibody group or PD-1 antibody combined PEG-IFNα group. PD-1 antibody will be injected intravenously once per 3 weeks for 24 weeks, and PEG-IFNα will be injected subcutaneously once a week for 48 weeks. The primary outcomes are the rate of HBsAg loss at 24 weeks. For safety analysis, adverse events in different groups will be compared. Ethics and dissemination This study has been approved by the Ethics Committee of the Fifth Medical Center of the Chinese PLA General Hospital (KY-2023-12-86-3). All results of the study will be submitted to a peer-reviewed journal. Trial registration number NCT06357806.
Open AccessSafety and efficacy of PD-1 antibody combined with pegylated interferon α for functional cure in nucleos(t)ide analogues-suppressed chronic hepatitis B patients: protocol for a multicentre randomised controlled trial
Introduction The functional cure of chronic hepatitis B (CHB) is an ideal goal of therapy, as it is associated with improved long-term outcomes. Patients with low levels of HBsAg have higher rates of functional cure by pegylated interferon α (PEG-IFNα) therapy, and similar results have been observed in patients treated with PD-1 antibody. However, the combination therapy of PD-1 antibody and PEG-IFNα for promoting functional cure has not been studied. This study protocol aims to evaluate the efficacy and safety of a novel combined strategy, PD-1 antibody combined with PEG-IFNα therapy, in nucleos(t)ide analogues (NAs)-treated CHB patients. Methods and analysis This is a prospective, multicentre, open-label, randomised controlled study. Virologically suppressed CHB patients by NAs therapy will be recruited and randomised into PEG-IFNα group, PD-1 antibody group or PD-1 antibody combined PEG-IFNα group. PD-1 antibody will be injected intravenously once per 3 weeks for 24 weeks, and PEG-IFNα will be injected subcutaneously once a week for 48 weeks. The primary outcomes are the rate of HBsAg loss at 24 weeks. For safety analysis, adverse events in different groups will be compared. Ethics and dissemination This study has been approved by the Ethics Committee of the Fifth Medical Center of the Chinese PLA General Hospital (KY-2023-12-86-3). All results of the study will be submitted to a peer-reviewed journal. Trial registration number NCT06357806.
- Open Access
- 29 July 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 238
Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights
Decompensated liver cirrhosis (DLC) is characterized by severe liver dysfunction and immune dysregulation, posing significant treatment challenges. Mesenchymal stromal cell (MSC) therapy has shown promise in DLC treatment, but the optimal dosing strategies and dose-dependent therapeutic mechanisms in humans remain unclear, limiting its clinical application. We conducted sequential Phase Ia/Ib trials using a single-arm, dose-escalation design to evaluate the safety and tolerability of MSC therapy in DLC patients while also exploring its immunomodulatory effects and gathering preliminary therapeutic signals. In Phase Ia, four dose cohorts received a single dose of MSCs: 5.0 × 10⁷, 1.0 × 10⁸, 1.5 × 10⁸, and 2.0 × 10⁸ cells. Patients were followed up on Days 3, 7, 14, and 28. Multiomics analyses, including single-cell RNA sequencing and cytometry by time of flight, were conducted to perform exploratory mechanistic analyses investigating immune cell dynamics and dose-dependent responses. Building on these findings, Phase Ib included two dose cohorts, each of which received three doses of MSCs administered one week apart: 1.0 × 10⁸ and 2.0 × 10⁸ cells per dose. Patients were followed up on Days 7, 14, 21, and 28 to further evaluate the safety and feasibility of multiple-dose regimens. The trials were registered at ClinicalTrials.gov (NCT05227846 and NCT05984303). MSC therapy demonstrated good safety and tolerability in both Phase Ia and Phase Ib trials, with no severe adverse events, dose-limiting toxicities, or serious unexpected adverse reactions observed up to Day 28. Multi-omics analyses revealed that higher MSC doses elicited stronger immunomodulatory effects, particularly by modulating monocyte subsets. In particular, myxovirus resistance 1 positive (MX1+) monocytes, a key monocyte population, exhibited dose-dependent changes and were identified as a mediator of MSC-induced immunomodulation. These effects were sustained for up to seven days post-treatment but diminished by Day 14. Preliminary clinical signals included improvements in Child–Pugh scores, Model for End-Stage Liver Disease scores, liver function markers, and quality-of-life metrics, particularly in the higher-dose and multiple-dose groups. This study demonstrates the safety and tolerability of MSC therapy in patients with DLC and provides the first human-based evidence on the dose‒effect relationship and optimal administration regimens. The identification of MX1+ monocytes as a critical mediator highlights the potential of MSC therapy to modulate immune dysfunction in DLC. These findings offer valuable insights for optimizing MSC therapy and informing the design of future efficacy-focused clinical trials.
- 29 July 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 238
Open AccessDose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights
Decompensated liver cirrhosis (DLC) is characterized by severe liver dysfunction and immune dysregulation, posing significant treatment challenges. Mesenchymal stromal cell (MSC) therapy has shown promise in DLC treatment, but the optimal dosing strategies and dose-dependent therapeutic mechanisms in humans remain unclear, limiting its clinical application. We conducted sequential Phase Ia/Ib trials using a single-arm, dose-escalation design to evaluate the safety and tolerability of MSC therapy in DLC patients while also exploring its immunomodulatory effects and gathering preliminary therapeutic signals. In Phase Ia, four dose cohorts received a single dose of MSCs: 5.0 × 10⁷, 1.0 × 10⁸, 1.5 × 10⁸, and 2.0 × 10⁸ cells. Patients were followed up on Days 3, 7, 14, and 28. Multiomics analyses, including single-cell RNA sequencing and cytometry by time of flight, were conducted to perform exploratory mechanistic analyses investigating immune cell dynamics and dose-dependent responses. Building on these findings, Phase Ib included two dose cohorts, each of which received three doses of MSCs administered one week apart: 1.0 × 10⁸ and 2.0 × 10⁸ cells per dose. Patients were followed up on Days 7, 14, 21, and 28 to further evaluate the safety and feasibility of multiple-dose regimens. The trials were registered at ClinicalTrials.gov (NCT05227846 and NCT05984303). MSC therapy demonstrated good safety and tolerability in both Phase Ia and Phase Ib trials, with no severe adverse events, dose-limiting toxicities, or serious unexpected adverse reactions observed up to Day 28. Multi-omics analyses revealed that higher MSC doses elicited stronger immunomodulatory effects, particularly by modulating monocyte subsets. In particular, myxovirus resistance 1 positive (MX1+) monocytes, a key monocyte population, exhibited dose-dependent changes and were identified as a mediator of MSC-induced immunomodulation. These effects were sustained for up to seven days post-treatment but diminished by Day 14. Preliminary clinical signals included improvements in Child–Pugh scores, Model for End-Stage Liver Disease scores, liver function markers, and quality-of-life metrics, particularly in the higher-dose and multiple-dose groups. This study demonstrates the safety and tolerability of MSC therapy in patients with DLC and provides the first human-based evidence on the dose‒effect relationship and optimal administration regimens. The identification of MX1+ monocytes as a critical mediator highlights the potential of MSC therapy to modulate immune dysfunction in DLC. These findings offer valuable insights for optimizing MSC therapy and informing the design of future efficacy-focused clinical trials.
- Open Access
- 11 June 2025
- Published by Wolters Kluwer Health in Infectious Diseases & Immunity
- Vol. 5 (4) , 303-305
Immune reconstitution inflammatory syndrome presenting as genital ulcers due to herpes simplex virus: A case report
Immune reconstitution inflammatory syndrome (IRIS) is a collection of inflammatory disorders characterized by the paradoxical worsening of preexisting infections processes following the initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-infected individuals. Diagnosing IRIS accurately and promptly remains challenging in areas with limited medical resources. Herpes simplex virus-2 (HSV-2) is highly endemic in sub-Saharan Africa and is one of the primary opportunistic pathogens underlying IRIS, manifesting as mucocutaneous lesions. Here, we report a case of HSV-2-associated IRIS presenting as a genital ulcer, confirmed through nanopore high-throughput sequencing and successfully treated with acyclovir antiviral therapy. This study emphasizes the importance of clinicians maintaining proficiency in recognizing IRIS manifestations and being aware of region-specific opportunistic pathogens, both essential for timely diagnosis and etiology-directed therapy.
- 11 June 2025
- Published by Wolters Kluwer Health in Infectious Diseases & Immunity
- Vol. 5 (4) , 303-305
Open AccessImmune reconstitution inflammatory syndrome presenting as genital ulcers due to herpes simplex virus: A case report
Immune reconstitution inflammatory syndrome (IRIS) is a collection of inflammatory disorders characterized by the paradoxical worsening of preexisting infections processes following the initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-infected individuals. Diagnosing IRIS accurately and promptly remains challenging in areas with limited medical resources. Herpes simplex virus-2 (HSV-2) is highly endemic in sub-Saharan Africa and is one of the primary opportunistic pathogens underlying IRIS, manifesting as mucocutaneous lesions. Here, we report a case of HSV-2-associated IRIS presenting as a genital ulcer, confirmed through nanopore high-throughput sequencing and successfully treated with acyclovir antiviral therapy. This study emphasizes the importance of clinicians maintaining proficiency in recognizing IRIS manifestations and being aware of region-specific opportunistic pathogens, both essential for timely diagnosis and etiology-directed therapy.